Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line

Inclusion Criteria:

1. Be at least 18 years of age
2. Have a confirmed diagnosis of MM
3. Starting lenalidomide treatment for MM (due to relapsed or refractory disease) after one prior treatment.
4. Have personally signed and dated a legally effective written informed consent form prior to admission to the study.
5. Must be willing and able to understand and comply with the study requirements.

Exclusion Criteria:

1. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening.
2. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.